Charges Against Pharma Reps for Unlawful Sales of Nearly 70M Opioid Pills.

Ten executives, sales representatives, and brokers from pharmaceutical distribution have been charged for their involvement in the illegal sale of nearly 70 million opioid pills.

Charges have been brought against five executives from pharmaceutical distribution companies, along with five sales representatives and brokers, in the Southern District of Texas, Southern District of Florida, Eastern District of Missouri, and Eastern District of North Carolina. This action is part of a broader enforcement effort concerning the illegal distribution of nearly 70 million opioid pills and more than 30 million doses of other frequently abused prescription medications to suspected pill-mill pharmacies in the Houston area.

Court documents reveal that the opioids in question—oxycodone, hydrocodone, and hydromorphone—were offered in various strengths and forms. However, the distributors reportedly focused on selling these drugs primarily in their most potent and commonly abused immediate-release pill versions, which fetched higher prices on the black market. Additionally, they allegedly provided prescription drug enhancers like alprazolam, carisoprodol, and promethazine with codeine syrup, known for intensifying the effects of the opioids. It is claimed that these distributors charged their customers in Houston significantly more than what a legitimate pharmacy would typically charge.

“The defendants, including pharmaceutical drug distributors, allegedly exploited the opioid crisis for profit — selling dangerous and addictive drugs to pill-mill pharmacies at above-market prices, knowing that the drugs would end up on the black market,” said Principal Deputy Assistant Attorney General Nicole M. Argentieri, head of the Justice Department’s Criminal Division. “The drugs had a staggering black-market value of over $1.3 billion. These charges represent the Justice Department’s largest criminal enforcement action targeting executives, brokers, and alleged pill-mill pharmacy owners for unlawfully distributing opioids and other commonly abused drugs. Our message is clear: we will not hesitate in our pursuit of those involved in dumping addictive pharmaceutical drugs onto the streets.”

The charging documents claim that the defendants primarily focused on pill-mill pharmacies in and around Houston, which is known nationally as a hotspot for the illegal diversion of pharmaceutical opioids. The distributors attempted to evade the Drug Enforcement Administration (DEA)’s scrutiny through various tactics, including adhering to what one defendant referred to as a “blueprint” for staying under the radar: setting high prices, imposing low purchasing limits on controlled substances, and implementing compliance measures that were merely for show. Furthermore, all the distributors operated from outside Texas, distancing themselves from their Houston-area pill-mill pharmacy clients and the communities suffering from the consequences of their alleged actions.

“The defendants in the charges announced today are alleged to be responsible for significantly contributing to the devastation caused by the opioid crisis by knowingly supplying pill-mill pharmacies and coaching pharmacy operators on how to evade law enforcement detection. According to the charging documents, they knowingly sold bulk narcotics to drug traffickers and to pharmacies they knew were selling to drug traffickers,” said DEA Administrator Anne Milgram. “As alleged, these defendants — owners, CEOs, executives, brokers — put profits over the health and safety of the American public. No one is above the law. If you contribute to the opioid epidemic, if you profit from the devastation of communities, we will hold you accountable. I commend the collaboration between DEA’s Diversion Control Division, our field divisions in St. Louis, Miami, Atlanta, Phoenix, Louisville and Houston, and our other state and federal law enforcement partners whose dedication to this investigation led us here today.”

“The distributors that sourced pills into the Houston area may be located across the country in Arizona, Florida, Maryland, California, North Carolina, and elsewhere, but they targeted Houston, helping to make it a known ‘hot zone’ for drug diversion,” said U.S. Attorney Alamdar S. Hamdani for the Southern District of Texas. “This office will always support the prosecution of individuals who try to thwart law enforcement and oversight by operating across state lines, posing as legitimate businesses, while in reality poisoning our district by targeting pill mills with precisely the drugs at the heart of our country’s addiction crisis. While there remain others who will be held accountable in the future, these cases build on this district’s history of systematically dismantling pill-mill clinics, pharmacies, and the often-violent drug-trafficking organizations, responsible for selling these pills in our community.”

“The use of protocols outside of common industry practice has contributed to the current opioid epidemic. To boost their profits, bad actors facilitate the distribution of opioids without medical necessity, threatening the lives and health of the public and the integrity of the Medicare program,” said Deputy Inspector General for Investigations Christian J. Schrank of the Department of Health and Human Services Office of Inspector General (HHS-OIG). “Our agency, working with our law enforcement partners, will continue to thoroughly investigate such schemes.”

“The FBI is dedicated to stopping dangerous controlled drugs from ending up in the wrong hands in communities across the country,” said Assistant Director Chad Yarbrough of the FBI Criminal Investigative Division. “These charges are another example of our continued multi-prong attack on those who contribute to the opioid crisis. The FBI and our partners investigate crimes at every level from the wholesaler pharmaceutical companies supplying the local pill-mill pharmacies to those selling the dangerous drugs on the street and black-market. We will not let anyone cash in and take advantage of people dealing with a drug addiction.”

“Supplying diverted prescription drugs undermines FDA safeguards designed to protect the public, compromising public safety for personal gain,” said Assistant Commissioner Justin Green of the Food and Drug Administration’s Office of Criminal Investigations (FDA-OCI). “This investigation is a clear demonstration that the FDA will not stop pursuing and bringing to justice those who put the public health at risk.”

“Today’s charges are a reminder of the continued danger of the opioid epidemic and the resolve of the investigative and legal teams,” said Special Agent in Charge Jonathan Ulrich of the U.S. Postal Service’s Office of Inspector General (USPS-OIG). “Anyone, including corporate executives, who knowingly facilitates opioid abuse will be held accountable for their greed and total disregard for safety.”

According to court documents, the following individuals were charged as part of today’s enforcement action:

A federal district court judge will determine any sentence after considering the U.S. Sentencing Guidelines and other statutory factors.

Leave a Reply

Your email address will not be published. Required fields are marked *